CORRECTION – OpGen Reports Fourth Quarter and Full Year : vimarsana.com

ROCKVILLE, Md., March 30, 2023 (GLOBE NEWSWIRE) -- In a release published March 29, 2023 under the same headline by OpGen, Inc. (Nasdaq: OPGN), the...

Related Keywords

Vienna , Wien , Austria , China , Ukraine , Beijing , Russia , Chinese , Oliver Schacht , Curetis Gmb , Albert Weber , Gene Panel , Opgen Investor Press Contact , Edison Group , European Investment Bank , International Number , Exchange Commission , Securities Exchange , Technology Platform , Opgen Inc , Nasdaq , Foundation For Innovative New Diagnostics , Full Year , Chief Financial Officer , Beijing Clear Biotech , Ares Genetics , Innovative New Diagnostics , Dial In Number , United Statesa , Curetis Gmbh , Ares Genetics Gmbh , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , Nasdaq Capital Market , Gen Investor , Press Contact , Months Ended December , Ended December , Nasdaq Opgn , Pgen , Nc , Arnings , Usiness Update , Evenue , Ompletion , Uccessful , Ommercial , Ti , Da , Linical Trial , Ata Readout , Ebinar , De Novo , 023 , Ospital ,